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Background: Despite the preclinical outcomes and biologic significance of the presence of the human epidermal
growth factor receptor-2 (HER2) extracellular domain (ECD), there is little evidence supporting the measurement of
ECD levels in any clinical setting. The aim of this study was to determine the prevalence of elevated serum HER2 ECD
levels, the association between these levels and tissue HER2 overexpression, and the potential clinical prognostic value
of HER2 ECD in primary invasive breast cancer.
Methods: Serum HER2 ECD levels were examined preoperatively in 2,862 consecutive stage I–III primary breast cancer
patients between 2007 and 2009. Serum HER2 ECD levels were measured by chemiluminescence immunoassay (ADVIA
Centaur), and the tissue HER2 status was assessed by immunohistochemistry and fluorescence in situ hybridization.
The cutoff value for the serum level of HER2 ECD was set at 15.2 ng/ml.
Results: Among the 2,862 patients, 126 (4.4%) had elevated serum HER2 ECD levels, and HER2 was overexpressed
in the tumor tissue of 692 patients (24.2%), with a concordance of 78.7%. Multivariate analysis revealed that
elevated serum HER2 ECD was a significant independent prognostic factor for worse distant-metastasis-free
survival [DMFS; hazard ratio (HR) = 2.50, 95% confidence interval (CI) = 1.5–4.3, P = 0.001] and breast-cancer-specific
survival (BCSS; HR = 2.0, 95% CI = 1.1–3.8, P = 0.036), which were much stronger in patients with tissue HER2-positive
tumors (DMFS: HR = 3.8, 95% CI = 2.0–7.0, P < 0.001; BCSS: HR = 2.6, 95% CI = 1.2-5.3, P = 0.012).
Conclusions: Given the prevalence of HER2 expression, its measurement as an independent prognostic factor can be
clinically useful, particularly in patients with tissue HER2-positive tumors.
Keywords: HER2 extracellular domain, HER2 breast cancer, Prognostic factorBackground
Human epidermal growth factor receptor-2 (HER2) over-
expression or amplification in tumor tissue is reportedly
observed in 20–30% of primary breast cancers. Tissue
HER2 status is now routinely used as an important para-
meter for decision making regarding anti-HER2 therapy in
the neoadjuvant [1], adjuvant [2], and metastatic [3]
settings. The presence of HER2 in tumor tissues also adds
predictive and prognostic information regarding shorter
overall and disease-free survivals [4], preferential benefit* Correspondence: jongwonlee116@gmail.com
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unless otherwise stated.from doxorubicin [5-7], and possible resistance to tamoxi-
fen [8-10]. However, despite the continuous and varying
degrees of tissue HER2 expression, tumors are arbitrarily
dichotomized into HER2-positive and HER2-negative
groups based on immunohistochemistry (IHC) and fluor-
escence in situ hybridization (FISH) [11]. As a result, the
definition of tissue HER2 positivity remains a matter of
controversy [12-14]. In addition, there is recent evidence
that some tissue HER2-negative patients appear to benefit
from trastuzumab [12,15].
Serum HER2 extracellular domain (ECD) can be de-
tectable by the cleavage of transmembrane tissue HER2
protein which is probably mediated by a matrix metallo-
proteinase [16-18]. Given the same origin of each HER2
subcomponent in tissue and blood, the technical problems. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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urged the exploration of clinical utilities of serum HER2
ECD [19]. The quantification of serum HER2 ECD in pri-
mary breast cancer could theoretically enhance the sensi-
tivity of tissue HER2 testing in the minority population in
which HER2 expression is significant, but is not suffi-
ciently high to be considered as HER2-positive by the
American Society of Clinical Oncology (ASCO) and Col-
lege of American Pathologists (CAP) guidelines, possibly
due to tumor heterogeneity [11,20-22]. In the metastatic
setting, the findings of some studies further suggest that
HER2 ECD levels and changes therein reflect the patients’
responses to antiestrogen therapy [23,24], chemotherapy
[25,26], and trastuzumab [27,28]. There have been a few
positive results in the adjuvant setting, similar to the
metastatic setting [29-33], but most studies have ad-
dressed the relationship between abnormal HER2 ECD
levels and tissue expression positivity with contradictory
results. The current consensus is that although preopera-
tive HER2 ECD appears to be correlated with tumor size
and nodal involvement, it may not be related to tissue
HER2 status, especially in primary breast cancer, and there
is insufficient evidence to support incorporating measure-
ment of this parameter into the routine clinical manage-
ment of women with breast cancer as an independent
prognostic factor [14,34].
The aims of the present study were to establish the
prevalence of elevated HER2 ECD levels, and determine
whether there is an association between serum HER2
ECD levels and tissue HER2 overexpression in a large
number of patients with primary breast cancer, using a
single assay approved by the US Food and Drug Adminis-
tration (FDA). Furthermore, we sought to elucidate differ-
ences in any such association between various subgroups
of patients, as reported previously [35,36], and to deter-
mine the prognostic usefulness of HER2 ECD and derive
evidence for verifying previous equivocal reports [14,34].
Methods
Patients who were diagnosed with and had surgery for
stage I–III primary breast cancer at Asan Medical Center
between January 2007 and December 2009 were enrolled
for this study (n = 2,862). Patients with distant metastasis
at the time of diagnosis, bilateral cancer, and the initial
plan of neoadjuvant systemic therapy were excluded. All
of the patients’ information and tumor characteristics
were retrieved from our prospectively collected database.
The size of the tumor, regional lymph node (LN) status,
histologic grade, nuclear grade, presence of lymphovascu-
lar invasion (LVI), histological subtype, and immunohis-
tochemical status of estrogen receptors, progesterone
receptors, and HER2 were determined at our institute by
pathological analysis on formalin-fixed paraffin-embedded
tissue sections of the primary tumor excised at the time ofdefinitive surgery. Tumor staging followed the tumor-
node-metastasis classification of the 7th American Joint
Committee on Cancer [37]. This study was reviewed
and approved by the Institutional Review Board of Asan
Medical Center (20141162).
Tissue HER2 immunohistochemistry
Formalin-fixed, paraffin-embedded sections (4 μm in
thickness) were deparaffinized, dehydrated through a
graded alcohol series, and subjected to blocking with
hydrogen peroxide and allowed to dry for 10 min at RT,
followed by 20 min in an incubator at 65C. IHC was per-
formed in a BenchMark XT autostainer (Ventana Medical
Systems, Tucson, AZ) using OptiView DAB Detection Kit
(Ventana Medical Systems) for HER2 (cat. 800–4422,
clone 4B5, dilution 1:8, Ventana Medical Systems, Tucson,
AZ, USA).
The results were graded according to the level of col-
oring of cell membrane of cancer cells. The cases where
less than 10% of the tumors cells stained positively were
graded as 0, cases where membrane staining was partial
but occurred in greater than 10% of the tumor cells were
scored as 1+, cases where entire cell membranes stained
modestly were graded as 2+, and cases where entire cell
membranes stained strongly but occurred in greater than
30% of the tumor cells were graded 3+. Cases graded 3+
were automatically considered positive, while tumors
graded 2+ were further evaluated by fluorescence in situ
hybridization (FISH) using the Abbott PathVysion HER2
DNA Probe Kit protocol (Abbott Laboratories, Abbott
Park, Des Plaines, USA), with additional monitoring for
the progress of proteolytic digestion by propidium iodide
staining. Probe mixes were hybridized at 37°C between
14 and18h. After hybridizations, slides were washed in 2 ×
SSC/0.3% NP-40 at 72°C for 30 min, air dried, and coun-
terstained with DAPI. The results were reported as the ra-
tio between the average copy number of the HER2 gene
and that of the chromosome 17 centromere, analyzing 20
neoplastic nuclei. Specimens with a signal ratio of <1.8
were considered negative for HER2 gene amplification,
whereas those with a signal ratio > 2.2 were considered
positive for HER2 gene amplification. If a signal ratio fell
on or between the values of 1.8 and 2.2, we counted the
number of signals in an additional 20 nuclei in a second
target area. The signal ratio was then calculated from both
target areas (40 cells).
Serum HER2 ECD assay
Serum samples were obtained from breast cancer patients
at our cancer center at the time of cancer diagnosis; 5 ml
of blood was drawn into serum-separation tubes before
surgery and then subjected to chemiluminescence im-
munoassay. The serum HER2 ECD test is a two-site sand-
wich immunoassay using two monoclonal antibodies that
Table 1 Distributions of serum human epidermal growth factor receptor-2 (HER2) extracellular domain (ECD) levels
and proportions of patients with elevated serum HER2 ECD levels (i.e., >15.2 ng/ml) according to subgroups stratified
according to various clinicopathologic variables (n = 2,862)
Subgroup classified by
variables
n (%) Serum HER2 ECD level (ng/ml) Pa Patients with HER2 ECD >15.2 ng/ml
Mean ± SD Median (range) n %b
Total patients 2,862 (100%) 10.1 ± 9.4 9.2 (3.3–427.8) 126 4.4%
Age, years 0.149
≤ 34 172 (6%) 10.1 ± 5.6 8.8 (4.8–56.0) 10 5.8%
35–49 1,510 (53%) 9.8 ± 12.1 8.8 (3.3–427.8) 55 3.6%
≥ 50 1,180 (41%) 10.5 ± 9.4 9.8 (4.4–90.1) 61 5.2%
Stage <0.001
I/II 2,457 (86%) 9.6 ± 4.6 9.1 (3.3–184.3) 81 3.3%
III 405 (14%) 12.8 ± 22.1 10.1 (5.5–427.8) 45 11.1%
Tumor size, cm 0.001
≤ 2 1,676 (59%) 9.6 ± 5.1 9.0 (3.3–184.3) 51 3.0%
> 2 1,186 (41%) 10.8 ± 13.2 9.5 (3.8–427.8) 75 6.3%
Lymph node <0.001
Negative 1,749 (61%) 9.6 ± 3.0 9.0 (3.3–48.2) 55 3.1%
Positive 1,113 (39%) 11.0 ± 14.6 9.4 (4.3–427.8) 71 6.4%
Histologic grade
1/2 1,787 (64%) 9.7 ± 5.5 9.0 (3.8–184.3) 0.002 53 3.0%
3 1,025 (36%) 10.8 ± 13.8 9.5 (4.6–427.8) 71 6.9%
Unknown 50 2
Nuclear grade 0.006
1/2 1,775 (63%) 9.6 ± 5.4 9.0 (3.3–184.3) 45 2.5%
3 1,049 (37%) 10.6 ± 13.6 9.4 (4.6–427.8) 65 6.2%
Unknown 38 16
LVI 0.018
Negative 2,095 (76%) 9.8 ± 3.7 9.1 (3.3–67.5) 88 4.2%
Positive 660 (24%) 10.3 ± 8.5 9.3 (3.8–184.3) 29 4.4%
Unknown 107 9
Hormone-receptor status <0.001
Negative 916 (32%) 11.5 ± 15.0 9.8 (4.6–427.8) 85 9.3%
Positivec 1,940 (68%) 9.5 ± 4.7 9.0 (3.3–184.3) 41 2.1%
Unknown 6 0
Tissue HER2 status <0.001
Negative 2,168 (76%) 9.3 ± 4.3 8.9 (3.8–184.3) 22 1.0%
Positived 692 (24%) 12.8 ± 17.3 10.6 (3.3–427.8) 104 15.0%
Unknown 2 0
Definitive surgery <0.001
Conservation 1,781 (62%) 9.3 ± 2.5 8.9 (3.3–44.8) 38 2.1%
Mastectomy 1,081 (38%) 11.4 ± 14.9 9.7 (4.3–427.8) 88 8.1%
Radiotherapy 0.135
Yes 2,047 (72%) 9.9 ± 10.2 9.1 (3.3–427.8) 74 3.6%
No 813 (28%) 10.5 ± 7.1 9.6 (4.3–184.3) 52 6.4%
Unknown 2 0
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Table 1 Distributions of serum human epidermal growth factor receptor-2 (HER2) extracellular domain (ECD) levels
and proportions of patients with elevated serum HER2 ECD levels (i.e., >15.2 ng/ml) according to subgroups stratified
according to various clinicopathologic variables (n = 2,862) (Continued)
Chemotherapy <0.001
Yes 1,852 (65%) 10.6 ± 11.5 9.4 (4.3–427.8) 106 5.7%
No 1,007 (35%) 9.2 ± 2.6 8.9 (3.3–35.6) 20 2.0%
Unknown 3 0
Anti-HER2 therapy <0.001
Yes 264 (9%) 15.0 ± 27.2 11.0 (4.3–427.8) 53 20.1%
No 2,598 (91%) 9.6 ± 4.4 9.1 (3.3–184.3) 73 2.8%
aCalculated by ANOVA.
bPercentage calculated by dividing the number of patients with elevated serum HER2 ECD level (>15.2 ng/ml) by the total number of patients in each subgroup.
cEstrogen- and/or progesterone-receptor positive.
dGraded as 3+ on immunohistochemistry (IHC) or 2+ on fluorescence in situ hybridization in cases of IHC 2+.
LVI lymphovascular invasion.
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chemiluminescence (ADVIA Centaur System, Siemens
Healthcare, Tarrytown, NY, USA). Measurements were
performed strictly according to the manufacturer’s in-
structions and quality control was ensured. The serum
HER2 ECD assay for each patient was performed as part
of the routine preoperative work-up procedures at the
Department of Laboratory Medicine, and the results were
stored in our database. We used the manufacturer’s
recommended cutoff value of 15.2 ng/ml.
Statistical analysis
Distant-metastasis-free survival (DMFS) was defined as
the time from surgery to the first appearance of distant
metastasis. Breast-cancer-specific survival (BCSS) wasFigure 1 Histogram showing the frequencies of serum human epider
levels (ng/ml) in 2,862 patients with primary invasive breast cancer.defined as the time from surgery to the time of breast-
cancer-specific death. Correlations between elevated
serum HER2 ECD and several variables were evaluated
using the chi-square test, and the means of continuous
variables such as age and serum HER2 ECD among dif-
ferent groups were compared using ANOVA. Survival
curves were generated using the Kaplan-Meier method,
and the significance of survival differences among selected
variables was verified using the log-rank test. The Cox
proportional-hazards model was used to evaluate the in-
dependent prognostic effect of serum HER2 ECD on
DMFS and BCSS. Unless stated otherwise, the data are
presented as mean ± SD, and the cutoff for statistical
significance was set at P < 0.05. All statistical analyses were
performed using SPSS version 12.0 (SPSS, Chicago,
IL, USA).mal growth factor receptor-2 (HER2) extracellular domain (ECD)
Table 2 Baseline characteristics and association between dichotomized serum HER2 ECD level and clinicopathologic
variables
Characteristics Total group Subgroup with normal serum HER2
ECD level (≤15.2 ng/ml)
Subgroup with elevated serum
HER2 ECD level (>15.2 ng/ml)
Pa
n % n % n %
Total patients 2,862 100% 2,736 100% 126 100%
Serum HER2 ECD, ng/ml
Mean ± SD 10.1 ± 9.4 9.3 ± 1.9 27.3 ± 40.4 <0.001b
Median (range) 9.2 (3.3–427.8) 9.1 (3.3–15.2) 18.5 (15.3–427.8)
Age at diagnosis, years 0.860b
Mean ± SD 48.5 ± 9.9 48.5 ± 9.9 48.4 ± 10.3
Median (range) 48 (22–94) 48.0 (22–94) 49.0 (26–88)
Age subgroup, years
≤ 34 172 6% 162 6% 10 8% 0.100
35–49 1,510 53% 1,455 53% 55 44%
≥ 50 1,180 41% 1,119 41% 61 48%
Stage
I/II 2,457 86% 2,376 87% 81 64% <0.001
III 405 14% 360 13% 45 36%
Tumor size, cm
≤ 2 1,676 59% 1,625 59% 51 40% <0.001
> 2 1,186 41% 1,111 41% 75 60%
Lymph node
Negative 1,749 61% 1,694 62% 55 44% <0.001
Positive 1,113 39% 1,042 38% 71 56%
Histologic grade
1/2 1,787 64% 1,734 65% 53 43% <0.001
3 1,025 36% 954 35% 71 57%
Unknown 50 48 2
Nuclear grade
1/2 1,775 63% 1,730 64% 45 41% <0.001
3 1,049 37% 984 36% 65 59%
Unknown 38 22 16
LVI
Negative 2,095 76% 2,007 76% 88 75% 0.830
Positive 660 24% 631 24% 29 25%
Unknown 107 98 9
Hormone-receptor status
Negative 916 32% 831 30% 85 68% <0.001
Positivec 1,940 68% 1,899 70% 41 32%
Unknown 6 6 0
Tissue HER2 status
Negative 2,168 76% 2,146 79% 22 17% <0.001
Positived 692 24% 588 21% 104 83%
Unknown 2 2 0
Definitive surgery <0.001
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Table 2 Baseline characteristics and association between dichotomized serum HER2 ECD level and clinicopathologic
variables (Continued)
Conservation 1,781 62% 1,743 64% 38 30%
Mastectomy 1,081 38% 993 36% 88 70%
Radiotherapy
Yes 2,047 72% 1,973 72% 74 59% 0.001
No 813 28% 761 28% 52 41%
Unknown 2 2 0
Chemotherapy
Yes 1,852 65% 1,746 64% 106 84% <0.001
No 1,007 35% 987 36% 20 16%
Unknown 3 3 0
Anti-HER2 therapy
Yes 264 9% 211 8% 53 42% <0.001
No 2,598 91% 2,525 92% 73 58%
aCalculated by chi-square test except where stated otherwise.
bCalculated by t-test.
cEstrogen- and/or progesterone-receptor positive.
dGraded as 3+ on IHC or 2+ on fluorescence in situ hybridization in cases of IHC 2+.
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Patient characteristics
The age of the entire cohort (n = 2,862 patients) was
48.5 ± 9.9 years (range, 22–94 years), and the numbers
of patients at stages I, II, and III were 1,245 (43.5%),
1,212 (42.3%), and 405 (14.2%), respectively. LN metas-
tasis was detected in 1,113 patients (38.9%), and positive
hormone-receptor status was found in 1,940 patients
(67.8%). Tissue HER2 positivity was detected by IHC and
FISH in 692 patients (24.2%), among which 264 patientsFigure 2 Distribution of serum HER2 ECD levels according to tissue H
in red and black, respectively.(38.2%) received adjuvant anti-HER2 therapy with trastu-
zumab. The details of the patient characteristics are
summarized in Table 1.
Distribution and prevalence of preoperative serum HER2
ECD levels in primary breast cancer
The HER2 ECD level before surgery was 10.1 ± 9.4 ng/ml
(Table 1); 2,736 patients (95.6%) had an HER2 ECD level
of ≤15.2 ng/ml, while in 126 (4.4%) the HER2 ECD level
exceeded that cutoff value (Table 1 and Figure 1). TheER2 status: tissue HER2 positive and negative cases are depicted
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groups were 9.3 ± 1.9 and 27.3 ± 40.4 ng/ml, respectively
(Table 2).
The distribution of preoperative HER2 ECD levels,
which ranged from 3.3 to 427.8 ng/ml, shows a positive
skew (i.e., the mass of the distribution was concentrated
to the left of the histogram), and the presence of outliers
at extremely high values (Figure 1). The majority of the
extremely high values belonged to the tissue HER2-
positive group. When depicted again according to the
tissue HER2-expression, it was found that the tissue
HER2-positive group had more variable distributionTable 3 Prediction performance of tissue HER2 status and con
Group analyzeda Cross-table Pb




























aA diagnostic cutoff value of 15.2 ng/ml was used except where stated otherwise.
bCalculated by chi-square test.
cElevated serum HER2 ECD level.
dNormal serum HER2 ECD level.
eDefined as 3+ on IHC or amplification on fluorescence in situ hybridization in case
fTissue HER2 negative.
PPV positive predictive value, NPV negative predictive value.pattern than their tissue HER2-negative counterparts
(Table 1 and Figure 2).
Patients with elevated HER2 ECD levels were more likely
to have aggressive clinicopathologic variables (Table 2).
Age at diagnosis was not related to HER2 ECD levels
(Tables 1 and 2). The proportions of patients with
elevated ECD level according to various subgroups are
summarized in Table 1. In the tissue HER2-positive
subgroup, 15.0% of the patients had elevated HER2
ECD, which is more than three times the average
(4.4%). Furthermore, the proportion of patients with ele-




Sensitivity Specificity PPV NPP
1 78.7 15.0 99.0 82.5 78.5
1 70.4 54.9 75.3 41.5 84.0
1 80.3 11.2 99.1 76.4 80.4
1 76.2 19.5 98.9 87.3 75.4
1 80.4 9.6 99.2 75.8 80.5
1 78.7 13.3 98.9 79.2 78.7
1 73.3 28.3 98.5 91.1 71.1
s of IHC 2+.
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http://www.biomedcentral.com/1471-2407/14/929and aggressive tumors: 11.3% of those at stage III, 9.3% of
those with negative hormone-receptor status, 6.9% of
those with high-grade disease, 6.4% of those with positive
LN metastasis, and 6.3% of those with a tumor size
of >2 cm. Among the 2,168 patients with negative
tissue HER2 status, only 22 (1.0%) had a level of HER2
ECD greater than the cutoff value.Serum HER2 ECD levels and tissue HER2 status
Of the patients for whom tissue HER2 status could be de-
termined by IHC and/or FISH (n = 2,860), 692 (24.2%)
had a positive tissue HER2 status. There was a strong
statistical correlation between serum HER2 ECD levels
and tissue HER2 status in terms of the difference in serum
HER2 ECD values (12.8 ± 17.3 and 9.3 ± 4.3 ng/ml, re-
spectively; P < 0.001; Table 1) as well as the proportion of
patients with elevated serum HER2 ECD level (15.0% and
1.0%, respectively; P < 0.001; Table 1) in tissue HER2-
positive and -negative subgroups. The overall concordance
rate was 78.7%, with a sensitivity of 15.0% and a specificity
of 99.0%. In addition, a better sensitivity (54.9%) was
obtained when we applied a different cutoff value of
10.2 ng/ml (rather than 15.2 ng/ml), which has been
suggested as an alternative cutoff value for Korean pop-
ulations [31], but the superior specificity (75.3%) and
overall concordance rate (70.4%) were not retained
[Table 3-(1), (2)].Figure 3 Receiver operating characteristic (ROC) curves of serum HE
95% confidence interval (CI; dotted line). (A) The area under the ROC
CI = 0.679–0.714, P < 0.001). In subgroup analyses, AUCs tended to increas
(0.637–0.682)/0.783 (0.711–0.763) in lymph node (LN)-negative/-positive s
(0.695–0.746)/0.778 (0.734–0.818) in stage I/II/III subgroups. The P values oAs indicated in Figure 3 and Table 3, a series of receiver
operating characteristic (ROC) analyses was performed to
determine differences in the concordance between the
serum and tissue status according to various subgroups,
using the cutoff value of 15.2 ng/ml, as used in previous
studies [35,36]. There was a trend toward an improvement
in sensitivities and area under the ROC curve (AUC),
while retaining good specificities and concordance rates
(≥98.5% and ≥73.3% in all subgroups, respectively) with
disease status progression (LN negative vs positive: sensi-
tivity = 11.2% vs 19.5%; stage I vs II vs III: sensitivity = 9.6%
vs 13.3% vs 28.3%; LN negative vs positive: AUC = 0.659 vs
0.738; stage I vs II vs III: AUC = 0.620 vs 0.721 vs 0.778).
Prognostic value of serum HER2 ECD level
The median follow-up period of all the patients was
46 months (range, 0–75 months). The 5-year distant-
metastasis-free survival (DMFS) rate was 81.4% for pa-
tients with elevated HER2 ECD and 93.6% for those
with normal HER2 ECD (log-rank P < 0.001; Figure 4A);
and corresponding 5-year breast-cancer-specific survival
(BCSS) rates were 85.3% and 95.1% (log-rank P < 0.001;
Figure 5A).
Figures 4 and 5 show the results of subgroup ana-
lyses. In the log-rank test, an elevated HER2 ECD level
(i.e., >15.2 ng/ml) was of prognostic value in terms of
DMFS, irrespective of tumor size, hormone-receptor sta-
tus, and anti-HER2 therapy (Figure 4B,D,F). Furthermore,R2 ECD for predicting the status of tissue HER2 positivity with
curve (AUC) for the entire cohort of 2,860 patients was 0.697 (95%
e with indexes of the tumor extent: (B,C) AUC (95% CI) = 0.659
ubgroups; and (D–F) AUC (95% CI) = 0.620 (0.592–0.647)/0.720
f all ROC curves were <0.001.
Figure 4 Distant-metastasis-free survival (DMFS) according to serum HER2 ECD level. (A) DMFS according to serum HER2 ECD level
[elevated level (>15.2 ng/ml) vs normal level (≤15.2 ng/ml)] in the overall series. Elevated serum HER2 ECD level was an independent prognostic
factor [log-rank P < 0.001, adjusted hazard ratio (HR) = 2.5, and 95% CI = 1.5–4.3]. (B–F) Subgroup analyses by tumor size (B), LN status (C),
hormone-receptor status (D), tissue HER2 status (E), and anti-HER2 therapy (F). (A–F) Elevated serum HER2 ECD level was significantly prognostic in all
subgroups except in those with LN negativity (log-rank P = 0.148, adjusted HR = 1.7, 95% CI = 0.6–5.1) and negative tissue HER2 status
(log-rank P = 0.906, adjusted HR = 1.0, 95% CI = 0.1–7.2). All HRs were adjusted according to the following eight variables: tumor size, LN status, tumor
grade, lymphovascular invasion, tissue HER2 status, chemotherapy, antihormone therapy, and trastuzumab therapy.
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http://www.biomedcentral.com/1471-2407/14/929elevated HER2 ECD level was found to be a significant
prognostic factor in subgroups with positive LN status
and tissue HER2 overexpression (log-rank P < 0.001
and <0.001, respectively), but not in those with negative
LN and negative tissue HER2 status (log-rank P = 0.148
and 0.906, respectively; Figure 4C,−E). Although in
terms of BCSS, elevated HER2 ECD levels were signifi-
cant in all 2,862 patients (log-rank P < 0.001) and in
subgroups with any tumor size, with any LN status,
with positive hormone-receptor status, and with posi-
tive tissue HER2 status, adjusted hazard ratios (HRs)
calculated for each subgroup revealed none to beindependently significant, except in a subgroup with
positive tissue HER2 status [log-rank P < 0.001, ad-
justed HR = 2.6, 95% confidence interval (CI) = 1.2–5.3;
Figure 5E]. Adjusted HRs of an elevated HER2 ECD
level (depicted in Figures 4 and 5) showed the same
trend of prognostic significance as in the log-rank test.
Statistically adjusted prognostic values in subgroups
according to anti-HER2 therapy in patients with posi-
tive tissue HER2 expression were observed significant
in both subgroups in terms of DMFS, but only in the
nontrastuzumab subgroup in terms of BCSS (Figures 4F
and 5F).
Figure 5 Breast-cancer-specific survival (BCSS) according to serum HER2 ECD level. (A) BCSS according to serum HER2 ECD level [elevated
(>15.2 ng/ml) vs normal (≤15.2 ng/ml)] in the overall series (B–F) Subgroup analyses by tumor size (B), LN status (C), hormone-receptor status (D),
tissue HER2 status (E), and anti-HER2 therapy (F). (A–F) No adjusted HRs in each subgroup were found to be independently significant, except in the
subgroup with positive tissue HER2 status (adjusted HR = 2.6, 95% CI = 1.2–5.3) and nontrastuzumab (adjusted HR = 8.2, 95% CI = 1.7–40.8). All HRs
were adjusted according to the following eight variables: tumor size, LN status, tumor grade, lymphovascular invasion, tissue HER2 status,
chemotherapy, antihormone therapy, and trastuzumab therapy.
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http://www.biomedcentral.com/1471-2407/14/929We classified all 2,860 patients into 3 subgroups ac-
cording to HER2 status [i.e., positive (+) and negative
(−)] in both tissue and serum: tissue–, irrespective of
serum status (n = 2,168), tissue+/serum– (n = 588), and
tissue+/serum + (n = 104). As shown in Figure 6, despite
tissue HER2 overexpression being a significant prognostic
factor in all patients for DMFS and BCSS (log-rank P =
0.015 and 0.035, respectively; data not shown), compari-
son of the three subgroups revealed that the DMFS and
BCSS did not differ between the tissue+/serum– and
tissue– subgroups (P = 0.793 and 0.627, respectively;
Figure 6A,B). The tissue+/serum + subgroup had themost ominous prognosis, which suggests a significant
role of serum HER2 ECD level as a prognosticator in
the tissue HER2-positive patients. In addition to apply-
ing the dichotomizing cutoff value of 15.2 ng/ml, four
subgroups categorized by serum HER2 ECD levels, only
in 692 patients with positive tissue HER2 status, exhibited
a trend toward a dose–response relationship in terms of
prognosis: higher serum HER2 ECD levels were associated
with worse DMFS and BCSS (Figure 6C,D).
The two Cox proportional-hazards models given in
Table 4 suggested that HER2 ECD level was a robust in-
dependent prognostic factor in patients with tissue HER2-
Figure 6 Distant-metastasis-free survival (DMFS) and breast-cancer-specific survival (BCSS) according to HER2 status in both tissue and
serum. DMFS (A) and BCSS (B) among three subgroups classified according to both tissue and serum HER2 status: tissue– irrespective of serum
status, tissue+/serum–, and tissue+/serum+. (C,D) There was a significant trend toward a reduction in survival with increasing serum HER2 ECD
values in only 692 patients with a positive tissue HER2 status.
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http://www.biomedcentral.com/1471-2407/14/929positive breast cancer, irrespective of the variable tenta-
tive cutoff values: elevated vs normal (HR = 3.788, 95%
CI = 2.034–7.058, P < 0.001, Table 4) and third/highest
quartile vs lowest quartile (third quartile: HR = 3.029,
95% CI = 1.003–9.152, P = 0.049; highest quartile: HR =
4.746, 95% CI = 1.591–14.160, P = 0.005; Table 4).
Discussion
The present study found that serum HER2 ECD level was
correlated with a poor prognosis in primary breast cancer,
and that patients with an elevated HER2 ECD level
(>15.2 ng/ml) had a worse DMFS and BCSS than those
with normal HER2 ECD levels. In particular, it was con-
firmed that its role as an independent prognostic factor
was clinically robust at various tentative cutoff values in
patients with positive tissue HER2 status.
There is still no general consensus as to a definitive
dichotomizing HER2 ECD cutoff value for clinical use, so
we adopted the most commonly used value of 15.2 ng/ml
to define elevated HER2 ECD. HER2 ECD levels were
previously reported to be elevated in 11.4% (range, 3.1–
34.1%) of primary breast cancer patients and 36.5% (range,
23–62%) of metastatic breast cancer patients [34]. In the
present study, elevated HER2 ECD levels were observed in
4.4% (126/2,862) of the primary breast cancer patients,
which is a noteworthy finding because it was derived froma large number of patients at a single institute and using a
single US FDA-approved assay. In addition, as shown in
Table 1, significant differences in the prevalence of
elevated HER2 ECD levels between the subgroups were
confirmed, which is in accordance with previous results
[30,36]. And, other studies have suggested that setting a
lower cutoff value such as 7.7 ng/ml and 10.2 ng/ml or
analyzing early stage patients could come with a better
outcome, however our additional study adjusted with
these did not show a better result (Figure 7). However, it
should be noticed that, our analysis did not address the
issues on more optimal cutoff values for HER2 ECD raised
by previous studies [31,38,39].
Interestingly, elevated serum HER2 ECD levels were
detected in 22 (1.0%) of the 2,168 tissue HER2-negative
patients (26.4 ± 35.6 ng/ml; range, 15.3–184.4 ng/ml).
Possible explanations for this are chance false-positivity,
normal elevation of serum HER2 ECD level as reported in
healthy controls [40], a minority of HER2-positive cells
being lower than the definition of tissue HER2 positivity
as its source [41], and genetic differences between individ-
uals with respect to matrix metalloproteinase activity,
which is responsible for HER2 release into the serum [39].
Since metastasis had occurred in only 1 of the 22 patients
in this subgroup, the clinical implication of unexpected
serum ECD elevation could not be further investigated.
Table 4 Cox proportional-hazards regression model for distant-metastasis-free survival (DMFS) and breast-cancer-
specific survival (BCSS) in 692 patients with tissue HER2-positive breast cancer
Variable DMFS BCSS
HR 95% CI P HR 95% CI P
Model with dichotomized serum HER2 ECD level, elevated vs normal
Serum HER2 ECD level, >15.2 ng/ml 3.788 2.034–7.054 <0.001a 2.564 1.230–5.343 0.012a
Tumor size, >2 cm 1.731 0.859–3.487 0.125 1.134 0.515–2.497 0.754
Lymph node positive 2.614 1.011–6.756 0.047a 2.428 0.812–7.257 0.112
Grade 3+ 1.972 1.069–3.638 0.030a 1.575 0.758–3.270 0.223
Lymphovascular invasion 2.625 1.419–4.855 0.002a 2.740 1.315–5.709 0.007a
Chemotherapy, yes 0.235 0.081–0.687 0.008a 0.303 0.085–1.078 0.065
Hormone therapy, yes 1.576 0.841–2.951 0.156 1.032 0.494–2.156 0.933
Trastuzumab, received 1.734 0.902–3.332 0.099 1.969 0.903–4.292 0.089
Model with four subgroups classified by serum HER2 ECD levels, each quartile group vs lowest-quartile subgroup
Serum HER2 ECD level,
Lowest quartile (reference) 1 1
Second quartile 1.827 0.549–6.078 0.326 1.008 0.224–4.529 0.992
Third quartile 3.029 1.003–9.152 0.049a 2.407 0.669–8.655 0.179
Highest quartile 4.746 1.591–14.160 0.005a 2.826 0.785–10.176 0.112
Tumor size, >2 cm 1.741 0.864–3.507 0.121 1.146 0.519–2.534 0.736
Lymph node positive 2.502 0.982–6.376 0.055 2.407 0.804–7.211 0.117
Grade 3+ 1.844 1.010–3.370 0.046a 1.844 1.010–3.370 0.046a
Lymphovascular invasion 2.303 1.250–4.240 0.007a 2.550 1.223–5.317 0.012a
Chemotherapy, yes 0.210 0.074–0.599 0.004a 0.273 0.078–0.957 0.042a
Hormone therapy, yes 1.443 0.784–2.655 0.238 1.038 0.501–2.150 0.920
Trastuzumab, received 1.930 1.013–3.677 0.045a 2.098 0.968–4.549 0.061
aSignificant at P < 0.05.
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http://www.biomedcentral.com/1471-2407/14/929In this study we observed a significant association
between elevated HER2 ECD level and the parameters of
tumor aggressiveness (Table 2). More patients had under-
gone mastectomy among those with an elevated HER2
ECD levels than in those with a normal HER2 ECD level.
This might be caused by the tumor characteristics being
more aggressive in the former subgroup than in the latter,
the cause of which was not fully established.
The association between serum HER2 ECD concentra-
tion and tissue HER2 status remains controversial in pri-
mary breast cancer, which may be attributable to the use
of different cutoff values, small samples, and different pa-
tient populations in the various studies. For now it seems
reasonable to suggest that serum HER2 ECD levels cannot
substitute for tissue HER2 expression, but can provide
additional information. The aim of the present study was
to compare the concordances according to the subgroups
and provide practical information when we suspected the
inherent imperfection of tissue HER2 results in the case of
elevated serum HER2 ECD levels. We applied two cutoff
values: 15.2 ng/ml, which has been approved by the US
FDA; and 10.2 ng/ml, which has been suggested as a moreappropriate cutoff value for the Korean population [31].
Although a lower cutoff value could yield a higher sensi-
tivity and negative predictive value (Table 3), it negatively
affected the specificity and positive predictive value. In
our opinion, in view of the adjunctive role of serum HER2
ECD level, the cutoff of 15.2 ng/ml may have greater clin-
ical utility because higher specificity and positive predict-
ive values are mandatory to reduce the likelihood of false
suspicion of tissue HER2 status due to the abnormal
serum HER2 ECD level. Unlike previous studies [35,36],
the present findings suggest that significant correlations
between the expression of tissue HER2 and serum HER2
ECD level exist in primary breast tumor, regardless of
whether the primary tumor is early or advanced (Table 3).
However, the finding that AUCs increased as the indexes
of tumor extent increased should not be overlooked
(Figure 3).
Despite the relatively short follow-up, the inclusion of a
large sample enabled us to demonstrate the poor prognos-
tic role of HER2 ECD level. Moreover, we determined that
tissue HER2 status had no prognostic impact on either
DMFS or BCSS in patients with a normal serum HER2
Figure 7 (See legend on next page.)
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Figure 7 Distant-metastasis-free survival (DMFS) and Breast-cancer-specific survival (BCSS) according to the serum HER2 ECD level by
the lower cutoffs and the early stages. (A) DMFS according to serum HER2 ECD level [elevated level (>10.2 ng/ml) vs normal level (≤10.2 ng/ml)]
in breast cancer patients with stage I and II. (B) BCSS according to serum HER2 ECD level [elevated level (>10.2 ng/ml) vs normal level (≤10.2 ng/ml)]
in breast cancer patients with stage I and II (C) DMFS according to serum HER2 ECD level [elevated level (>7.7 ng/ml) vs normal level (≤7.7 ng/ml)] in
breast cancer patients with stage I and II (D) BCSS according to serum HER2 ECD level [elevated level (>7.7 ng/ml) vs normal level (≤7.7 ng/ml)] in
breast cancer patients with stage I and II (E) DMFS according to serum HER2 ECD level [elevated level (>10.2 ng/ml) vs normal level (≤10.2 ng/ml)] in
breast cancer patients with stage I, II and III (F) BCSS according to serum HER2 ECD level [elevated level (>10.2 ng/ml) vs normal level (≤10.2 ng/ml)] in
breast cancer patients with stage I, II and III (G) DMFS according to serum HER2 ECD level [elevated level (>7.7 ng/ml) vs normal level (≤7.7 ng/ml)] in
breast cancer patients with stage I, II and III (H) BCSS according to serum HER2 ECD level [elevated level (>7.7 ng/ml) vs normal level (≤7.7 ng/ml)] in
breast cancer patients with stage I, II and III.
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http://www.biomedcentral.com/1471-2407/14/929ECD level. Thus, the serum HER2 ECD level can be a
valuable prognostic factor in patients with primary breast
cancer with tissue HER2 overexpression (Figure 6 and
Table 4). The persistent adverse prognostic value of ele-
vated HER2 ECD levels in stage I/II early breast cancer
could reflect the presence of micrometastases or high
rates of HER2 cleavage and shedding, with the production
of truncated cell-associated fragments that contain the
signaling kinase domain that is activated in the absence of
the ECD. As a result, these tumors with a deregulated
growth-promoting pathway could behave more aggres-
sively [30].
To clarify the possibility of false-positive results in the
present study in terms of prognosis according to the arbi-
trary cutoff value of 15.2 ng/ml, we validated its prognos-
tic role among continuous subgroups classified relative to
the quartile values of serum HER2 ECD levels in tissue
HER2-positive tumors: the lowest-quartile, median, and
highest-quartile values were 8.7, 10.6, and 13.1 ng/ml,
respectively. The Kaplan-Meier curves (Figure 6C, D) and
multivariate analysis revealed that the third- and highest-
quartile subgroups independently had an ominous prog-
nosis in terms of DMFS (third quartile: HR = 3.029, 95%
CI = 1.003–9.152, P = 0.049; highest quartile: HR = 4.746,
95% CI = 1.591–14.160, P = 0.005; Table 4).
The possibility of an association between HER2 ECD
level and trastuzumab response was assessed in 264 pa-
tients receiving trastuzumab and in 428 patients without
trastuzumab administration. We found that HER2 ECD
level was a poor prognostic indicator, irrespective of the
treatment in terms of DMFS (Figure 4F). In terms of
BCSS, there did not appear to be a significant prognostic
role of elevated HER2 ECD level in the trastuzumab sub-
group (Figure 5F). This lack of a significant finding may
be attributable to the relatively short follow-up. Also, only
38.2% (264/692) of patients with HER2-positive tumors
had been treated with trastuzumab in the cohort. It is
partly related to the inclusion of patients with small tu-
mors. Our study did not include patients receiving neoad-
juvant systemic therapy. More importantly, the use of
trastuzumab in the adjuvant setting was just covered for
advanced breast cancer by the Korean national health in-
surance during the period of this study (2007 ~ 2009). Inpatients with tissue HER2 positive, T1 was 54.5% (377/
692), and N0 was 54.0% (374/692), which needs to be
taken into consideration. Due to the nature of a retro-
spective analysis without randomization, it was not pos-
sible to compare the responses or benefits of trastuzumab
among the subgroups of 261 patients who received this
drug with elevated (n = 53) and normal (n = 208) HER2
ECD levels.
While the present study is subject to the same limita-
tions as other retrospective studies, it provides robust evi-
dence supporting the valuable clinical utility of HER2
ECD level, drawn successfully because of the inclusion
of a large sample. The presented results indicate that a
preoperatively elevated HER2 ECD level reflects tumor
extension, with significantly higher values being found in
patients with larger tumors, with LN metastasis, or with
LVI, and that patients with an elevated HER2 ECD level
are more likely to develop distant metastasis irrespective
of their disease status.
Conclusions
Given the prevalence of HER2 ECD elevation, preoperative
serum HER2 ECD measurement can be clinically useful
in patients with tissue HER2-positive primary breast
cancer.
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